To improve progression-free survival (PFS) in MCL using a strategy of incorporating approaches of intensifying induction & intensifying consolidation with high dose chemo radiotherapy (HDT by administering an anthracycline-containing regimen in a dose dense fashion CHOP- or R-CHOP-14) followed by consolidation with ICE HDT/ASCT.

Researchers concluded that these data provide evidence that dose-dense induction with CHOP-14 or R-CHOP-14 and consolidation with ICE/HDT/ASCT appears to be safe and effective, with minimal acute toxicity Future therapy could incorporate all the successful elements of prior treatment programs with R-CHOP-14, R-ICE, and radioimmunotherapy with high dose chemotherapy conditioning regimen, followed by ASCT.

Official Title


Study Type

Phase II

Study Design

46 patients with newly diagnosed MCL underwent HDT/ASCT.Median age was 55 years; 74% were male; 72% had bone marrow involvement, 39% had GI involvement, 7% were in leukemic phase & 91% presented with stage IV disease. Splenomegaly was seen in 35%, B symptoms in 9%, KPS>70 in 93%, elevated LDH in 23%, and blastoid histology in 9%. Treatment:Induction – 4 to 6 cycles of CHOP-14 (43%), R-CHOP-14 (37%), or other doxorubicin-containing regimen (20%). Consolidation was performed with 2-3 cycles of ICE in 53% or R-ICE in 39%. Upfront treatment was well tolerated and permitted adequate stem cell collection and prompt transition to HDT/ASCT. Conditioning regimens were TBI/CY/VP-16 (59%) and BEAM (41%)Involved field radiation therapy was administered to 65%. Post-ASCT rituximab maintenance was given to 39%, with 57% of patients receiving rituximab as part of their treatment.

Further Details

Results:Anthracycline-based induction led to CRu of 44% and ORR of 98%.72% of patients were transplanted in CR, the remaining 28% were in PR. At a median follow-up of 2.5 years (range 0.4-8.0 years) 17% of the patients have died and 24% have had progressive disease. The median OS and PFS have not been reached (lower 95% CI, 5.7 years and 4.4 years, respectively). The 5-year PFS and OS are 58% and 83%, respectively.

Study Start

Eligibility & Criteria

Indication: Newly diagnosed MCL

Total Enrolment


Contact Details

Abstract 2072 ASH 2005

All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.